TOKYO, Mar 11 (Pulse News Wire) – Cyfuse Biomedical K.K. (4892.T) reported robust revenue growth of approximately 4.2 times compared to the previous fiscal year, driven by sales of its 3D cell products such as "Human 3D Mini Liver®" and various contract services.
The company's 2025 fiscal year saw significant progress across multiple areas, including regenerative medicine, drug development support, and device technology. In the regenerative medicine sector, preparations for clinical trials of three pipeline developments—peripheral nerve regeneration and bone cartilage regeneration—are set to begin in 2026. Additionally, the expansion of the "Human 3D Mini Liver®" product lineup and enhanced sales infrastructure accelerated market penetration in the drug development support area. Device technology advancements also progressed rapidly, enhancing production techniques and manufacturing environments for regenerative medical products. Profitability improved due to cost efficiencies achieved through the application of the company’s proprietary platform technology across multiple domains, resulting in a narrower loss margin compared to the previous fiscal year.
Looking ahead, Cyfuse aims to build a resilient revenue base combining stable income from device sales and consumables, rights-based revenues from collaboration fees, and future growth from regenerative medical product launches. Regarding functional cellular devices (FCD products), Cyfuse plans to strengthen sales of "Human 3D Mini Liver®" while expanding the FCD product range globally and entering new sectors. These high-precision evaluation models contribute to efficient drug development processes and are expected to serve as alternative methods to animal testing in the future. Additionally, Cyfuse listed on the Fukuoka Securities Exchange (Q-Board market) alongside the Tokyo Stock Exchange to enhance regional presence and promote further academic-industrial-government cooperation in Fukuoka. This dual listing strategy aims to diversify shareholder composition and improve long-term stock liquidity.
🟢 Confidence: High AI-translated content.